Drugs & Aging

, Volume 25, Issue 11, pp 955–962 | Cite as

Effects of Lamotrigine on Mood in Older Adults with Epilepsy and Co-Morbid Depressive Symptoms

An Open-Label, Multicentre, Prospective Study
  • Toufic A. Fakhoury
  • J. Mitchell Miller
  • Anne E. Hammer
  • Alain Vuong
Original Research Article


Background: Both epilepsy and depressive symptoms are more prevalent in older individuals than in any other age group. Furthermore, depressive symptoms are among the most common interictal psychiatric co-morbid disorders in people with epilepsy. For these reasons, pharmacological treatment of epilepsy that might also confer antidepressant effects may be particularly beneficial in older patients. In this respect, lamotrigine is of considerable interest amongst antiepileptic drugs (AEDs) because it has proven thymoleptic activity.

Objective: These analyses, conducted on a data set drawn from a previously reported, open-label, multicentre, prospective study, examined the effect of lamotrigine on mood in adults aged ≥50 years with epilepsy and co-morbid depressive symptoms. All subjects were receiving background AED therapy at baseline.

Methods: Of the 158 subjects enrolled in the initial study, 40 adults (24 women, 16 men) met the age criterion for these analyses. The study consisted of a screening/baseline phase and four treatment phases over 36 weeks: lamotrigine escalation phase (7 weeks); lamotrigine maintenance or adjunctive therapy phase (12 weeks); concomitant AED withdrawal phase (5 weeks); and lamotrigine monotherapy phase (12 weeks). Psychometric evaluation of mood utilized the Beck Depression Inventory (BDI-II), Center for Epidemiological Studies Depression Scale (CES-D), the Neurological Disorders Depression Inventory in Epilepsy (NDDI-E) and the Profile of Mood States (POMS). Scores at the end of the adjunctive and monotherapy phases were compared with baseline scores. Lower scores on these scales indicate less depressive symptomatology.

Results: Mean baseline scores for the BDI-II, CES-D, NDDI-E and POMS were 15.8, 24.3, 13.8 and 57.7, respectively. Change scores were statistically significant (p < 0.01) compared with baseline at the end of the adjunctive and monotherapy phases for all four psychometric measures of mood, with the exceptions of BDI-II and NDDI-E at the end of the adjunctive phase.

Conclusions: The older adults in these analyses presented with low to moderate levels of depressive symptoms. Addition of lamotrigine to background AED therapy demonstrated antidepressant activity similar to that for the whole sample in the initial study. Given that the onset and prevalence of epilepsy are higher in older adults than in any other age group, pharmacological treatment for epilepsy in older patients that might also confer antidepressant therapy may be particularly beneficial.



Presented in part at the Annual Meeting of the American Epilepsy Society, December 2005, Washington, DC, USA.

This study was supported by GlaxoSmithKline (GSK) Research and Development (Protocol LAM40117).

Participating investigators were: Imran Ali, Toledo, OH; Greg Anderson, Lexington, KY; Ricardo Ayala, Tallahassee, FL; Jhablall Balmakund, St Cloud, MN; John J. Barry, Stanford, CA; Lawrence Eisenman, St Louis, MO; Nasrollah Eslami, Alabaster, AL; Toufic Fakhoury, Lexington, KY; Robert Frere, Greenville, NC; Daniel Garber, Asheville, NC; Jeffrey Gitt, Phoenix, AZ; Justin Graff, Tupelo, MS; Mark Harris, Atlanta, GA; Richard Hull, Huntsville, AL; Jack Klapper, Denver, CO; Ruben Kuzniecky, Birmingham, AL; David Labiner, Tucson, AZ; Paul Mazzeo, Beaufort, SC; William McElveen, Bradenton, FL; Elliot Michel, Natrona Heights, PA; Martha Morrell, New York, NY; Shiva Natarajan, Memphis, TN; Nancy Rodgers-Neame, Tampa, FL; Ken Ng, Ocala, FL; Juan Ochoa, Jacksonville, FL; Luis Pagani, Crestview Hills, KY; Mrugendra Patel, Richlands, VA; Joanne Rogin, Golden Valley, MN; Dwight St. Clair, Wichita, KS; Michael Sauter, Greensburgh, PA; Eleonora Spokoyny, Santa Ana, CA; Mutaz Tabbaa, Panama City, FL; Robert Tillett, Louisville, KY; Alexandre Todorov, Northport, AL; Mary Ann Werz, Cleveland, OH, USA.

Toufic Fakhoury has received speakers bureau honoraria and research grants from GSK. J. Mitchell Miller, Anne Hammer and Alain Vuong are employees of GSK. J. Mitchell Miller and Alain Vuong hold stock options in GSK.

Medical writing services were provided by Turner Medical Communications LLC.


  1. 1.
    Olafsson E, Ludvigsson P, Gudmundsson G, et al. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol 2005; 4: 627–34PubMedCrossRefGoogle Scholar
  2. 2.
    American Association of Geriatric Psychiatry. Geriatrics and mental health: the facts [online]. Available from URL: www.aagponline.org/prof/facts_mh.asp [Accessed 2008 Sep 17]
  3. 3.
    Alpass FM, Neville S. Loneliness, health, and depression in older males. Aging Ment Health 2003; 7: 212–6PubMedCrossRefGoogle Scholar
  4. 4.
    Cacioppo JT, Hughes ME, Waite LJ, et al. Loneliness as a specific risk factor for depressive symptoms: cross-sectional and longitudinal analyses. Psychol Aging 2006; 21: 140–51PubMedCrossRefGoogle Scholar
  5. 5.
    Lenze EJ, Mulsant BH, Dew MA, et al. Good treatment outcomes in late-life depression with comorbid anxiety. J Affect Disord 2003; 77: 247–54PubMedCrossRefGoogle Scholar
  6. 6.
    Whyte EM, Basinski J, Farhi P, et al. Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. J Clin Psychiatry 2004; 65: 1634–41PubMedCrossRefGoogle Scholar
  7. 7.
    Dew MA, Whyte EM, Lenze EJ, et al. Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. Am J Psychiatry 2007; 164: 892–9PubMedCrossRefGoogle Scholar
  8. 8.
    Hermann B, Seidenberg M, Bell B. Psychiatric comorbidity in chronic epilepsy: identification, consequences, and treatment of major depression. Epilepsia 2000; 41: S31–41PubMedCrossRefGoogle Scholar
  9. 9.
    Ettinger A, Reed M, Cramer J. Depression and comorbidity in community-based patients with epilepsy or asthma. Neurology 2004; 63: 1008–14PubMedCrossRefGoogle Scholar
  10. 10.
    Gallo JJ, Coyne JC. The challenge of depression in late life: bridging science and service in primary care [editorial]. JAMA 2000; 284: 1570–2PubMedCrossRefGoogle Scholar
  11. 11.
    Penninx BW, Deeg DJ, van Eijk JT, et al. Changes in depression and physical decline in older adults: a longitudinal perspective. J Affect Disord 2000; 61: 1–12PubMedCrossRefGoogle Scholar
  12. 12.
    Griffith HR, Martin RC, Bambara JK, et al. Older adults with epilepsy demonstrate cognitive impairments compared with patients with amnesic mild cognitive impairment. Epilepsy Behav 2006; 8: 161–8PubMedCrossRefGoogle Scholar
  13. 13.
    Kobau R, Gilliam F, Thurman DJ. Prevalence of self-reported epilepsy or seizure disorder and its associations with self-reported depression and anxiety: results from the 2004 Health-Styles Survey. Epilepsia 2006; 47: 1915–21PubMedCrossRefGoogle Scholar
  14. 14.
    Potter GG, Steffens DC. Contribution of depression to cognitive impairment and dementia in older adults. Neurologist 2007; 13: 105–17PubMedCrossRefGoogle Scholar
  15. 15.
    Cramer JA, Hammer AE, Kustra RP. Improved mood states with lamotrigine in patients with epilepsy. Epilepsy Behav 2004; 5: 702–7PubMedCrossRefGoogle Scholar
  16. 16.
    Gilliam F, Kanner AM. Treatment of depressive disorders in epilepsy patients. Epilepsy Behav 2002; 3: 2–9PubMedCrossRefGoogle Scholar
  17. 17.
    Ghaemi SN, Gaughan S. Novel anticonvulsants: a new generation of mood stabilizers. Harvard Rev Psychiatry 2000; 8: 1–7Google Scholar
  18. 18.
    Pugh MJV, Foreman PJ, Berlowitz DR. Prescribing antiepileptics for the elderly: differences between guideline recommendations and clinical practice. Drugs Aging 2006; 23: 861–75PubMedCrossRefGoogle Scholar
  19. 19.
    Giorgi L, Gomez G, O’Neill F, et al. The tolerability of lamotrigine in elderly patients with epilepsy. Drugs Aging 2001; 18: 621–30PubMedCrossRefGoogle Scholar
  20. 20.
    Leach JP, Brodie MJ. Lamotrigine: clinical use. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 889–95Google Scholar
  21. 21.
    Fakhoury TA, Barry JJ, Miller JM, et al. Lamotrigine in patients with epilepsy and comorbid depressive symptoms. Epilepsy Behav 2007; 10: 155–62PubMedCrossRefGoogle Scholar
  22. 22.
    Beck AT, Steer RA, Brown GK. Beck Depression Inventory manual. 2nd ed. San Antonio (TX): The Psychological Corporation, 1996Google Scholar
  23. 23.
    Gilliam FG, Barry JJ, Hermann BP, et al. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol 2006; 5: 399–405PubMedCrossRefGoogle Scholar
  24. 24.
    Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. J Appl Psychol Measurement 1977; 1: 385–401CrossRefGoogle Scholar
  25. 25.
    Myers JK, Weismann MM. Use of self-report symptom scale to detect depression in community samples. Am J Psychiatry 1980; 137: 1081–4PubMedGoogle Scholar
  26. 26.
    Schulberg HC, Saul M, McClelland M, et al. Assessing depression in primary medical and psychiatric practices. Arch Gen Psychiatry 1985; 42: 1164–70PubMedCrossRefGoogle Scholar
  27. 27.
    Lorr M, McNair DM, Droppleman LF. Manual: Profile of Mood States. San Diego (CA): Educational and Industrial Testing Service, 1971Google Scholar
  28. 28.
    Nyenhuis DL, Yamamoto C, Luchetta T, et al. Adult and geriatric normative data and validation of the Profile of Mood States. J Clin Psychol 1999; 55(1): 79–86PubMedCrossRefGoogle Scholar
  29. 29.
    Cramer JA, Perrine K, Devinsky O, et al. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia 1998; 39: 81–8PubMedCrossRefGoogle Scholar
  30. 30.
    Gilliam F, Carter J, Vahle V. Tolerability of antiseizure medications: implications for health outcomes. Neurology 2004; 63: S9–12PubMedCrossRefGoogle Scholar
  31. 31.
    Kanner AM, Kozak AM, Frey M. The use of sertraline in patients with epilepsy. Is it safe? Epilepsy Behav 2000; 1: 100–5CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Toufic A. Fakhoury
    • 1
  • J. Mitchell Miller
    • 2
  • Anne E. Hammer
    • 3
  • Alain Vuong
    • 2
  1. 1.Department of NeurologyUniversity of KentuckyLexingtonUSA
  2. 2.Neurosciences Medicines Development CentreGlaxoSmithKlineResearch Triangle ParkUSA
  3. 3.Biomedical Data SciencesGlaxoSmithKlineResearch Triangle ParkUSA

Personalised recommendations